Pegsunercept

Pegsunercept is a biopharmaceutical that was under development for the treatment of rheumatoid arthritis. It is a pegylated form of a soluble tumor necrosis factor receptor (TNFR) that acts as a TNF inhibitor.

History

Pegsunercept was developed by Amgen, a multinational biopharmaceutical company. The drug was in Phase III clinical trials for the treatment of rheumatoid arthritis but development was discontinued.

Mechanism of Action

Pegsunercept works by inhibiting the action of tumor necrosis factor (TNF), a substance in the body that causes inflammation. It does this by binding to TNF and preventing it from activating TNF receptors. This reduces inflammation and helps to slow down the progression of diseases that are caused by an overactive immune response, such as rheumatoid arthritis.

Clinical Trials

Pegsunercept underwent Phase III clinical trials for the treatment of rheumatoid arthritis. However, the development of the drug was discontinued for unknown reasons.

See Also

• Biopharmaceutical
• Rheumatoid arthritis
• Tumor necrosis factor
• TNF inhibitor
• Amgen

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia